logo

PRAX

Praxis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

PRAX fundamentals

Praxis (PRAX) released its earnings on Aug 4, 2025: revenue was 0 (YoY -100.00%), missed estimates; EPS was -3.31 (YoY -90.23%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-3.31
-90.23%
Report date
Aug 4, 2025
PRAX Earnings Call Summary for Q2,2025
  • Breakthrough Efficacy: Vormatrigine achieved 56% median seizure reduction and 22% seizure-free rate in RADIANT, outperforming cenobamate even in high-dose patients.
  • Fast-Acting & Tolerable: 54% of patients responded by week 1, with only 20% adverse event rate vs. competitors.
  • Strategic Pipeline: POWER2 (40mg dose added) and POWER3 (monotherapy) studies to expand label, targeting $2-3B hyperrefractory epilepsy market.
  • Mood Benefits: Observed mood improvements may support broader CNS applications, with formal endpoints added to future trials.
EPS
Revenue

Revenue & Expenses

Key Indicators

Praxis (PRAX) key financial stats and ratios, covering profitability, financial health, and leverage.
Praxis (PRAX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Praxis (PRAX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Praxis (PRAX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Praxis (PRAX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Praxis (PRAX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield